Remicade (infliximab) denied as not medically necessary by UnitedHealthcare?

This UnitedHealthcare commercial policy (effective 02.01.2026) addresses the use of infliximab products including Avsola, Inflectra, Remicade, and Renflexis , and applies to billing codes J1745, Q5103, Q5104, and Q5121 . UHC designates Avsola and Inflectra as the preferred infliximab products for UHC commercial plans , and members already on Remicade, Renflexis, or other non-preferred infliximab product will be required to change therapy to Inflectra or Avsola unless they meet the exception criteria . To obtain Remicade specifically, the policy requires documentation of a trial of at least 14 weeks of Inflectra or Avsola resulting in minimal clinical response, OR a physician attestation that in their clinical opinion the clinical response would be expected to be superior with Remicade than with Inflectra and Avsola , or alternatively documentation of intolerance, contraindication, or adverse event to the preferred biosimilars with a physician attestation that the same event would not be expected to occur with Remicade . Indication-specific criteria require disease-appropriate step therapy — for example, ankylosing spondylitis requires history of failure to two NSAIDs at maximally indicated doses, each used for at least 4 weeks, unless contraindicated, or prior treatment with a systemic targeted immunomodulator FDA-approved for ankylosing spondylitis ; plaque psoriasis requires greater than or equal to 3% body surface area involvement, or palmoplantar, facial, or genital involvement plus failure of a topical therapy. Patients must not be receiving infliximab in combination with another systemic targeted immunomodulator (e.g., adalimumab, Cimzia, Enbrel, Orencia, Simponi, Rinvoq, Xeljanz) for treatment of the same indication , and dosing must be according to FDA-labeled dosing for the indication . Prior authorization is required, and the policy notes the patient must not have FDA-labeled contraindications and must be tested for latent TB per prescribing information, with treatment begun if positive .

- For forced biosimilar switching: cite the ACR position that coverage for non-preferred products should consider patient-specific exception criteria, and ACR has urged UHC to allow existing patients to continue on their current medication and proposed additional exception criteria for patient protection ; also reference AGA's negotiated exceptions that adult patients currently on induction of Remicade for less than 18 months will not be required to switch, and adult patients having a flare of active disease, and hence are not stable, will not be required to switch - For pediatric IBD denials of Remicade continuation: cite United's agreement to modify its coverage policy to allow pediatric patients 16 years of age and younger currently on Remicade to remain on Remicade if that is the recommendation of the treating physician , supported by NASPGHAN/AGA/ACG/ASGE consensus - For step therapy in Crohn's disease: cite the ACG Clinical Guideline for Crohn's Disease in Adults and AGA Care Pathway recommending early anti-TNF therapy for moderate-to-severe disease and high-risk features (fistulizing, stricturing, perianal, young age at diagnosis) — aligns with UHC's own high-risk criteria language - For step therapy in rheumatoid arthritis: cite the 2021 ACR Guideline for RA Treatment supporting biologic DMARDs (including TNFi) after inadequate response to methotrexate; for ankylosing spondylitis cite the 2019 ACR/SAA/SPARTAN AS Guideline strongly recommending TNFi after NSAID failure - For plaque psoriasis criteria: cite the AAD-NPF 2019 Guidelines of Care for the Management of Psoriasis with Biologics supporting infliximab for moderate-to-severe disease and special-site involvement (palmoplantar, facial, genital), matching UHC's BSA/special-site criteria - For non-medical switching/efficacy concerns: cite the NOR-SWITCH randomized controlled trial (Jørgensen et al., Lancet 2017) demonstrating non-inferiority of CT-P13 biosimilar to originator infliximab — but conversely, a documented loss of response or infusion reaction on a biosimilar meets UHC's own exception pathway for Remicade - For concomitant biologic denial: clarify in the appeal that the patient is transitioning therapies (not on simultaneous biologics) with appropriate washout, addressing UHC's combination-therapy exclusion language

## Why UnitedHealthcare May Deny Remicade (Infliximab) for Medical Necessity

UnitedHealthcare's medical-necessity denials for Remicade (infliximab) typically occur when the submitted clinical documentation does not clearly satisfy all of the criteria in UHC's current coverage determination policy for infliximab. Common gaps include insufficient documentation of disease severity, incomplete prior-treatment history, absence of the specialist's clinical rationale, or a mismatch between the submitted diagnosis code and the specific indication covered in the policy. The denial reflects a documentation deficit as often as it reflects a genuine clinical disagreement.

## Why This Denial Is Appealable

Medical-necessity denials are fully appealable, and the appeal process is specifically designed to allow the treating clinician to supply the evidence and reasoning that was absent or unclear in the original submission. Because UHC's reviewers can only evaluate what is in the record, a well-organized supplemental submission that directly maps clinical documentation to each policy criterion — and that includes a strong specialist letter — resolves the majority of these denials at the internal level.

## Federal Appeal Framework

• Internal appeal: Under ERISA §503 and ACA §2719, you have the right to a full-and-fair internal review. UHC must provide the specific clinical rationale and the criteria used in the denial. Review the denial letter carefully — each criterion cited must be addressed in your appeal.
• External review: If the internal appeal is denied, an independent external review is available within approximately four months. External reviewers apply objective clinical standards and are not bound by UHC's internal policy interpretations.
• Expedited review: Request this simultaneously with the standard appeal if withholding treatment would seriously jeopardize the patient's health or ability to regain maximum function.

## Documentation to Gather

1. UHC's current infliximab coverage policy — download directly from UHC's provider portal. Identify every listed criterion: qualifying diagnosis, disease-severity requirements, required prior therapies, required specialist type, and any monitoring or documentation requirements. 2. Specialist letter of medical necessity — from the treating gastroenterologist, rheumatologist, or relevant specialist. Must address each UHC policy criterion by name and map the patient's specific clinical situation to each requirement. 3. Disease-severity documentation — chart notes with objective disease-activity assessments referenced by date, not by specific score numbers; describe the clinical picture in narrative terms that align with the severity language in UHC's policy. 4. Prior-treatment history — dated records of each previously tried agent, including duration, response, and reason for transition to infliximab. 5. Diagnosis confirmation — pathology, endoscopy, imaging, or other objective confirmation of the underlying condition as appropriate to the diagnosis.

## Criteria-Mapping Structure

Build a two-column table:

| UHC Medical-Necessity Criterion (copy verbatim) | Patient Chart Evidence (document + date) | |---|---| | Qualifying diagnosis | Specialist note, ICD code, objective confirmation | | Disease severity requirement | Chart note with clinical description | | Prior therapy requirement | Dated medication history with outcomes | | Prescriber type / attestation | Specialty, NPI, signed letter | | Any additional criteria in policy | Corresponding documentation |

Every unanswered criterion is a reason for another denial. A complete, systematic response is the most effective appeal strategy.